SEARCH

SEARCH BY CITATION

References

  • 1
    Gordon R, Fung J, Tzakis AG, Todo S, Stieber A, Bronsther O, et al. Liver transplantation at the University of Pittsburgh, 1984 to 1990. Clin Transpl 1991; 1991: 105117.
  • 2
    Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619626.
  • 3
    Demetris AJ, Todo S, Van Thiel D, Fung JJ, Iwaki Y, Sysyn G, et al. Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations. Am J Pathol 1990; 137: 667676.
  • 4
    Samuel D, Müller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 18421847.
  • 5
    Yoffe B, Burns DK, Bhatt HS, Combes B. Extrahepatic hepatitis B virus DNA sequences in patients with acute hepatitis B infection. Hepatology 1990; 12: 187192.
  • 6
    Mason A, Yoffe B, Noonan C, Mearns M, Campbell C, Kelley A, et al. Hepatitis B virus DNA in peripheral-blood mononuclear cells in chronic hepatitis B after HBsAg clearance. Hepatology 1992; 16: 3641.
  • 7
    Lake J, Wright T. Liver transplantation for patients with hepatitis B: what have we learned from our results? Hepatology 1991; 13: 796799.
  • 8
    Lauchart W, Müller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 1987; 19: 40514053.
  • 9
    Mentha G, Giostra E, Perrin L, Widmann JJ, Stelling MJ, Easton J, et al. Prevention of viral recurrence following liver transplantation for post-hepatitis B and B-delta cirrhosis. Schweiz Med Wochenschr 1994; 124: 637641.
  • 10
    Marcellin P, Samuel D, Areias J, Loriot MA, Arulnaden JL, Gigou M, et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 1994; 19: 612.
  • 11
    Rakela J, Wooten RS, Batts KP, Perkins JD, Taswell HF, Krom RA. Failure of interferon to prevent recurrent hepatitis B infection in hepatic allograft. Mayo Clin Proc 1989; 64: 429432.
  • 12
    Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother 1989; 33: 17651773.
  • 13
    Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992; 36: 27472757.
  • 14
    Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrobial agents and chemotherapy 1994; 38: 24542457.
  • 15
    Pue MA, Pratt SK, Fairless AJ, Fowles S, Laroche J, Georgiou P, et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother 1994; 33: 119127.
  • 16
    Vere Hodge RA, Darlison SJ, Earnshaw DL, Readshaw SA. Use of isotopically chiral [4′-13C]penciclovir and 13C NMR to determine the specificity and absolute configuration of penciclovir phosphate esters formed in HSV-1 and HSV-2 infected cells and by HSV-1-encoded thymidine kinase. Chirality 1993; 5: 583588.
  • 17
    Tsiquaye KN, Slomka MJ, Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J Med Virol 1994; 42: 306310.
  • 18
    Shaw T, Amor P, Civitico G, Boyd M, Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother 1994; 38: 719723.
  • 19
    Zoulim F, Dannaoui E, Trépo C. Inhibitory effect of penciclovir, the active metabolite of famciclovir, on the priming of hepadnavirus reverse transcription (abstract). Hepatology 1995; 22(4): 329A.
  • 20
    Main J, Brown J, Karayiannis P, Georgiou P, Boyd M, Prince W, et al. A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. (Poster P1C1/38). J Hepatol 1994; 21: S32A (suppl 1).
  • 21
    Böker KH, Ringe B, Krüger M, Pichlmayr R, Manns MP. Prostaglandin E plus famciclovir—a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994; 57: 17061708.
  • 22
    Tillmann H, Trautwein C, Walker D, Michitaka K, Kubicka S, Böker K, Manns M. Clinical relevance of mutations in the precore genome of the hepatitis B virus. Gut 1995; 37: 568573.
  • 23
    Eason J, Freeman RJ, Rohrer RJ, Lewis WD, Jenkins R, Dienstag J, Cosimi AB. Should liver transplantation be performed for patients with hepatitis B?: Transplantation 1994; 57: 15881593.
  • 24
    McMillan J, Shaw P, Angus P, Locarnini S. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995; 22: 3643.
  • 25
    Davies S, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ, Williams R. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150157.
  • 26
    Mora N, Klintmalm GB, Poplawski SS, Cofer JB, Husberg BS, Gonwa TA, Goldstein RM. Recurrence of hepatitis B after liver transplantation: does hepatitis-B-immunoglobulin modify the recurrent disease? Transplant Proc 1990; 22: 15491550.
  • 27
    Samuel D, Bismuth A, Serres C, Arulnaden JL, Reynes M, Benhamou JP, et al. HBV infection after liver transplantation in HBsAg positive patients: experience with long-term immunoprophylaxis. Transplant Proc 1991; 23(1 Pt 2): 14921494.
  • 28
    Terrault NA, Hahn J, Ascher N, Wright TL. Prophylactic therapy is the most important factor determing recurrence in hepatitis B surface antigen (HBsAg+) patients undergoing liver transplantation (OLT) [Abstract]. Hepatology 1994; 20: 138A.
  • 29
    Lavine J, Lake JR, Ascher NL, Ferrell LD, Ganem D, Wright TL. Persistent hepatitis B virus following interferon alfa therapy and liver transplantation. Gastroenterology 1991; 100: 263267.
  • 30
    Lau JY, Bird GL, Naoumov NV, Williams R. Hepatic HLA antigen display in chronic hepatitis B virus infection. Relation to hepatic expression of HBV genome/gene products and liver histology. Dig Dis Sci 1993; 38: 88895.
  • 31
    Lok AS, Novick DM, Karayiannis P, Dunk AA, Sherlock S, Thomas HC. A randomized study of the effects of adenine arabinoside 5′-monophosphate (short or long courses) and lymphoblastoid interferon on hepatitis B virus replication. Hepatology 1985; 5: 11321138.
  • 32
    Weller IV, Lok AS, Mindel A, Karayiannis P, Galpin S, Monjardino J, et al. Randomised controlled trial of adenine arabinoside 5′-monophosphate (ARA-AMP) in chronic hepatitis B virus infection. Gut 1985; 26: 745751.
  • 33
    Berk L, Schalm SW, de Man R, Heytink RA, Berthelot P, Brechot C, et al. Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multicentre randomized controlled trial. J Hepatol 1992; 14: 305309.
  • 34
    Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. Pilot study of ribavirin and interferon-beta for chronic hepatitis B. Hepatology 1993; 18: 258263.
  • 35
    Staschke KA, Colacino JM, Mabry TE, Jones CD. The in vitro anti-hepatitis B virus activity of FIAU [1-(2′-deoxy-2′-fluoro-1-beta-D-arabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell. Antiviral Res 1994; 23: 4561.
  • 36
    Brahams D. Deaths in US fialuridine trial. Lancet 1994; 343: 14941495.
  • 37
    McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie A, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 10991105.
  • 38
    Sallie R, Kleiner D, Richardson F, Conjeevaram H, Zullo S, Mutimer D, et al. Mechanisms of FIAU induced hepatotoxicity. Hepatology 1994; 20: 209A.
  • 39
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. Double-blind randomized, three month, dose-ranging trial of lamivudine for chronic hepatitis B. Hepatology 1994; 20: 199A.
  • 40
    Tyrrel D, Mitchell MC, De Man RA. Phase II trial of lamivudine for chronic hepatitis B. Hepatology 1993; 18: 112A.
  • 41
    Gish RG, Lau JYN, Brooks L, Fang JWS, Steady SL, Imperial JC, et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996; 23(1): 17.
  • 42
    Angus P, Richards M, Bowden S, Ireton J, Sinclair R, Jones R, et al. Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection. J Gastroenterol Hepatol 1993; 8: 353357.
  • 43
    Jurim O, Martin P, Winston D, Shaked A, Csete M, Holt C, et al. Ganciclovir fails to prevent graft rejection following orthotopic liver transplantation for chronic hepatitis B. Hepatology 1994; 20: 138A.
  • 44
    Gugenheim J, Crafa F, Fabiani P, Militerno G, Goubaux B, Saint PM, et al. Recurrence of virus B hepatitis after liver transplantation. Gastroenterol Clin Biol 1992; 16: 430433.
  • 45
    Flowers M, Sherker A, Sinclair SB, Greig PD, Cameron R, Phillips MJ, et al. Prostaglandin E in the treatment of recurrent hepatitis B infection after orthotopic liver transplantation. Transplantation 1994; 58: 183192.